Avadel Pharmaceuticals to Provide a Corporate Update and Report Third Quarter 2024 Financial Results on November 12
Avadel Pharmaceuticals (Nasdaq: AVDL) announced it will host a conference call and live webcast on November 12, 2024, at 8:30 a.m. ET to discuss its third quarter 2024 financial results and provide a corporate update. The conference call can be accessed by dialing (800) 579-2543 with conference ID AVADEL. A live webcast will be available on the company's investor relations website, and a replay will be archived for 90 days.
Avadel Pharmaceuticals (Nasdaq: AVDL) ha annunciato che ospiterà una chiamata in conferenza e una diretta web il 12 novembre 2024 alle 8:30 a.m. ET per discutere i risultati finanziari del terzo trimestre 2024 e fornire un aggiornamento societario. La chiamata in conferenza può essere accessibile componendo il numero (800) 579-2543 con ID conferenza AVADEL. Una diretta streaming sarà disponibile sul sito web delle relazioni con gli investitori della società e una registrazione sarà archiviata per 90 giorni.
Avadel Pharmaceuticals (Nasdaq: AVDL) anunció que realizará una conferencia telefónica y una transmisión en vivo el 12 de noviembre de 2024 a las 8:30 a.m. ET para discutir sus resultados financieros del tercer trimestre de 2024 y proporcionar una actualización corporativa. La conferencia telefónica se puede acceder marcando el (800) 579-2543 con el ID de conferencia AVADEL. Una transmisión en vivo estará disponible en el sitio web de relaciones con los inversores de la compañía, y una grabación se archivará durante 90 días.
Avadel Pharmaceuticals (Nasdaq: AVDL)는 2024년 11월 12일 오전 8:30 ET에 2024년 3분기 재무 결과를 논의하고 회사 업데이트를 제공하기 위해 컨퍼런스 콜 및 라이브 웹캐스트를 개최한다고 발표했습니다. 컨퍼런스 콜은 (800) 579-2543로 전화하여 회의 ID AVADEL로 접근할 수 있습니다. 라이브 웹캐스트는 회사의 투자자 관계 웹사이트에서 제공되며, 재생은 90일 동안 아카이브됩니다.
Avadel Pharmaceuticals (Nasdaq: AVDL) a annoncé qu'il organisera une conférence téléphonique et un webcast en direct le 12 novembre 2024 à 8h30 ET pour discuter de ses résultats financiers pour le troisième trimestre 2024 et fournir une mise à jour de l'entreprise. La conférence téléphonique peut être accessible en composant le (800) 579-2543 avec l'ID de conférence AVADEL. Un webcast en direct sera disponible sur le site web des relations avec les investisseurs de la société, et un replay sera archivé pendant 90 jours.
Avadel Pharmaceuticals (Nasdaq: AVDL) kündigte an, dass am 12. November 2024 um 8:30 Uhr ET eine Telefonkonferenz und ein Live-Webcast stattfinden werden, um die finanziellen Ergebnisse des dritten Quartals 2024 zu besprechen und ein Unternehmensupdate bereitzustellen. Die Telefonkonferenz kann unter der Nummer (800) 579-2543 mit der Konferenz-ID AVADEL erreicht werden. Ein Live-Webcast wird auf der Website für Investor Relations des Unternehmens verfügbar sein, und eine Aufnahme wird 90 Tage lang archiviert.
- None.
- None.
DUBLIN, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Tuesday, November 12, 2024, to provide a corporate update and discuss the Company's financial results for the third quarter ended September 30, 2024.
To access the conference call, investors are invited to dial (800) 579-2543 (U.S. and International) and reference the conference ID AVADEL. A live audio webcast of the call be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients seven years and older with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Courtney Mogerley
Precision AQ
Courtney.Mogerley@precisionAQ.com
(212) 698-8687
Media Contact:
Lesley Stanley
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162
FAQ
When will Avadel Pharmaceuticals (AVDL) report Q3 2024 earnings?
How can I access Avadel Pharmaceuticals' (AVDL) Q3 2024 earnings call?
How long will Avadel Pharmaceuticals' (AVDL) Q3 2024 earnings webcast be available?
